Cartesian Therapeutics (NASDAQ:RNAC) Given Buy Rating at Needham & Company LLC
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reissued by Needham & Company LLC in a note issued to investors on Monday,Benzinga reports. They currently have a $41.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 117.28% from the company’s current price. […]
More Stories
219,000 Shares in Vistra Corp. (NYSE:VST) Acquired by Vision Capital Corp
Vision Capital Corp bought a new stake in shares of Vistra Corp. (NYSE:VST – Free Report) during the third quarter,...
Whetstone Capital Advisors LLC Makes New Investment in 3M (NYSE:MMM)
Whetstone Capital Advisors LLC bought a new stake in 3M (NYSE:MMM – Free Report) during the third quarter, according to...
AmpliTech Group Announces Pricing of $1.4 Million Registered Direct OfferingHAUPPAUGE, N.Y., Nov. 25, 2024 – AmpliTech Group, Inc. (NASDAQ: AMPG, AMPGW) disclosed on November 25, 2024, the pricing details of a registered direct offering amounting to
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
Tesla, Inc. (NASDAQ:TSLA) Shares Bought by Independent Advisor Alliance
Independent Advisor Alliance lifted its position in shares of Tesla, Inc. (NASDAQ:TSLA – Free Report) by 4.9% during the third...
Study Links Constipation to Increased Heart Attack and Stroke Risk
By George Citroner A recent study reveals the connection between constipation and a higher risk of major adverse cardiac events...
SPDR Dow Jones Industrial Average ETF Trust (NYSEARCA:DIA) Sets New 1-Year High – What’s Next?
SPDR Dow Jones Industrial Average ETF Trust (NYSEARCA:DIA – Get Free Report)’s share price reached a new 52-week high on...